JP2022551950A5 - - Google Patents
Info
- Publication number
- JP2022551950A5 JP2022551950A5 JP2022522065A JP2022522065A JP2022551950A5 JP 2022551950 A5 JP2022551950 A5 JP 2022551950A5 JP 2022522065 A JP2022522065 A JP 2022522065A JP 2022522065 A JP2022522065 A JP 2022522065A JP 2022551950 A5 JP2022551950 A5 JP 2022551950A5
- Authority
- JP
- Japan
- Prior art keywords
- difluoro
- methyl
- amino
- cyclopropyl
- oxazepino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201914860A GB201914860D0 (en) | 2019-10-14 | 2019-10-14 | Inhibitor compounds |
| GB1914860.0 | 2019-10-14 | ||
| PCT/GB2020/052588 WO2021074620A1 (en) | 2019-10-14 | 2020-10-14 | [1,4]oxazepino[2,3-c]qui noli none derivatives as blc6 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022551950A JP2022551950A (ja) | 2022-12-14 |
| JP2022551950A5 true JP2022551950A5 (enExample) | 2023-10-19 |
| JP7668273B2 JP7668273B2 (ja) | 2025-04-24 |
Family
ID=68619494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022522065A Active JP7668273B2 (ja) | 2019-10-14 | 2020-10-14 | Ｂｃｌ６阻害剤としての［１，４］オキサゼピノ［２，３－ｃ］キノリノン誘導体 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12528826B2 (enExample) |
| EP (1) | EP4045510B1 (enExample) |
| JP (1) | JP7668273B2 (enExample) |
| KR (1) | KR20220083761A (enExample) |
| CN (1) | CN114650995A (enExample) |
| AU (1) | AU2020365518B2 (enExample) |
| CA (1) | CA3157716A1 (enExample) |
| ES (1) | ES3047908T3 (enExample) |
| GB (1) | GB201914860D0 (enExample) |
| IL (1) | IL292182B1 (enExample) |
| MX (1) | MX2022004419A (enExample) |
| WO (1) | WO2021074620A1 (enExample) |
| ZA (1) | ZA202203520B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3095371A1 (en) | 2018-04-13 | 2019-10-17 | Cancer Research Technology Limited | Bcl6 inhibitors |
| GB201914860D0 (en) | 2019-10-14 | 2019-11-27 | Cancer Research Tech Ltd | Inhibitor compounds |
| CA3154386A1 (en) | 2019-10-17 | 2021-04-22 | Michael Berlin | Bifunctional molecules containing an e3 ubiquitine ligase binding moiety linked to a bcl6 targeting moiety |
| KR20230171979A (ko) | 2021-04-16 | 2023-12-21 | 아비나스 오퍼레이션스, 인코포레이티드 | Bcl6 단백질 분해의 조절제 및 관련 사용 방법 |
| PE20250756A1 (es) | 2022-06-06 | 2025-03-13 | Treeline Biosciences Inc | Degradadores bifuncionales de bcl6 de quinolona triciclica |
| EP4536649A1 (en) | 2022-06-13 | 2025-04-16 | Treeline Biosciences, Inc. | Quinolone bcl6 bifunctional degraders |
| KR20250023481A (ko) | 2022-06-13 | 2025-02-18 | 트리라인 바이오사이언시스, 인크. | 1,8-나프티리딘-2-온 이종이작용성 bcl6 분해제 |
| KR20240161027A (ko) * | 2023-05-03 | 2024-11-12 | 인제대학교 산학협력단 | BTK 분해제 및 Bcl-6 분해제를 포함하는 암의 예방 또는 치료용 약학적 조성물 |
| AU2024331309A1 (en) * | 2023-09-01 | 2026-03-19 | Treeline Biosciences, Inc. | Tricyclic quinolone bcl6 bifunctional degraders |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0259572A (ja) | 1988-08-23 | 1990-02-28 | Mitsubishi Kasei Corp | ベンズイミダゾロン誘導体又はその塩類 |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| DE69720965T2 (de) | 1996-02-13 | 2004-02-05 | Astrazeneca Ab | Chinazolinderivate und deren verwendung als vegf hemmer |
| NZ331191A (en) | 1996-03-05 | 2000-03-27 | Zeneca Ltd | 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| CA2349616A1 (en) | 1998-12-04 | 2000-06-15 | Neurosearch A/S | New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| PT1154774E (pt) | 1999-02-10 | 2005-10-31 | Astrazeneca Ab | Derivados de quinazolina como inibidores de angiogenese |
| IL147309A0 (en) | 1999-07-21 | 2002-08-14 | Fujisawa Pharmaceutical Co | Benzimidazolone derivatives and pharmaceutical compositions containg the same |
| AU2001258628A1 (en) | 2000-05-31 | 2001-12-11 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| WO2001094311A1 (en) | 2000-06-08 | 2001-12-13 | Mitsubishi Pharma Corporation | Cytoprotectors |
| MXPA02012905A (es) | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Derivados de colquinol como agentes de dano vascular.. |
| MXPA02012903A (es) | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Derivados de colquinol como inhibidores de angiogenesis. |
| UY27304A1 (es) | 2001-05-24 | 2002-12-31 | Avanir Pharmaceuticals | Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación |
| WO2003095448A1 (en) | 2002-05-06 | 2003-11-20 | Bayer Pharmaceuticals Corporation | Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders |
| US7825132B2 (en) | 2002-08-23 | 2010-11-02 | Novartis Vaccines And Diagnostics, Inc. | Inhibition of FGFR3 and treatment of multiple myeloma |
| US20050256157A1 (en) | 2002-08-23 | 2005-11-17 | Chiron Corporation | Combination therapy with CHK1 inhibitors |
| WO2008011032A1 (en) | 2006-07-17 | 2008-01-24 | Amgen Inc. | Quinazoline and pyridopyrimidine derivatives as p38 kinase inhibitors |
| WO2008066887A2 (en) | 2006-11-30 | 2008-06-05 | Albert Einstein College Of Medicine Of Yeshiva University | Small molecule inhibitors of bcl6 |
| US8686008B2 (en) | 2007-08-16 | 2014-04-01 | The University Of Mississippi | Highly selective sigma receptor ligands |
| WO2009063240A1 (en) | 2007-11-16 | 2009-05-22 | Arrow Therapeutics Limited | 2,4-diaminopyrimidine derivatives useful as inhibitors of aurora kinase |
| SG187502A1 (en) | 2008-02-01 | 2013-02-28 | Takeda Pharmaceutical | Oxim derivatives as hsp90 inhibitors |
| AU2009314760B2 (en) | 2008-11-11 | 2011-11-10 | Je Il Pharmaceutical Co.,Ltd | Novel tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same |
| BRPI1006942A2 (pt) | 2009-01-23 | 2016-04-12 | Rigel Pharmaceuticals Inc | composto, composição farmacêutica, kit, métodos para inibir uma atividade de uma jak quinase, para tratar uma doença, para tratar a rejeição de transplante de aloenxerto em um receptor de transplante, para tratar uma reação de hipersensibilidade, e para inibir uma cascata de transdução de sinal, e, uso do composto |
| KR20120114355A (ko) | 2010-01-13 | 2012-10-16 | 글락소스미스클라인 엘엘씨 | 화합물 및 방법 |
| CA2840883C (en) | 2011-07-07 | 2019-07-16 | Merck Patent Gmbh | Substituted azaheterocycles |
| CA2877146C (en) | 2012-06-18 | 2020-10-20 | Dart Neuroscience (Cayman) Ltd | Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compounds |
| EP2964642B1 (en) | 2013-03-05 | 2017-11-15 | F. Hoffmann-La Roche AG | Inhibitors of bruton's tyrosine kinase |
| US9943506B2 (en) | 2013-06-17 | 2018-04-17 | Cornell University | BCL6 inhibitors as anticancer agents |
| CN105017159B (zh) | 2014-04-28 | 2019-05-17 | 四川大学 | 5-氟-2,4-二取代氨基嘧啶衍生物及其制备方法和用途 |
| US10266549B2 (en) | 2014-08-25 | 2019-04-23 | Salk Institute For Biological Studies | ULK1 inhibitors and methods using same |
| US20160060260A1 (en) | 2014-08-29 | 2016-03-03 | Board Of Regents, The University Of Texas System | Bromodomain inhibitors for treating disease |
| HK1244427A1 (zh) | 2014-12-06 | 2018-08-10 | Intra-Cellular Therapies, Inc. | 有机化合物 |
| WO2017007658A1 (en) | 2015-07-07 | 2017-01-12 | Rigel Pharmaceuticals, Inc. | A combination for immune mediated cancer treatment |
| US11001570B2 (en) * | 2016-12-13 | 2021-05-11 | Boehringer Ingelheim International Gmbh | 6-amino-quinolinone compounds and derivatives as BCL6 inhibitors |
| US11161839B2 (en) | 2017-05-26 | 2021-11-02 | The Institute Of Cancer Research: Royal Cancer Hospital | 2-quinolone derived inhibitors of BCL6 |
| JP7202315B2 (ja) | 2017-05-26 | 2023-01-11 | キャンサー・リサーチ・テクノロジー・リミテッド | ベンズイミダゾロン由来のｂｃｌ６阻害剤 |
| CA3095371A1 (en) | 2018-04-13 | 2019-10-17 | Cancer Research Technology Limited | Bcl6 inhibitors |
| GB201819136D0 (en) | 2018-11-23 | 2019-01-09 | Cancer Research Tech Ltd | Inhibitor compounds |
| GB201914860D0 (en) | 2019-10-14 | 2019-11-27 | Cancer Research Tech Ltd | Inhibitor compounds |
-
2019
- 2019-10-14 GB GB201914860A patent/GB201914860D0/en not_active Ceased
-
2020
- 2020-10-13 IL IL292182A patent/IL292182B1/en unknown
- 2020-10-14 US US17/768,174 patent/US12528826B2/en active Active
- 2020-10-14 AU AU2020365518A patent/AU2020365518B2/en active Active
- 2020-10-14 KR KR1020227016037A patent/KR20220083761A/ko active Pending
- 2020-10-14 JP JP2022522065A patent/JP7668273B2/ja active Active
- 2020-10-14 WO PCT/GB2020/052588 patent/WO2021074620A1/en not_active Ceased
- 2020-10-14 CA CA3157716A patent/CA3157716A1/en active Pending
- 2020-10-14 CN CN202080072281.5A patent/CN114650995A/zh active Pending
- 2020-10-14 MX MX2022004419A patent/MX2022004419A/es unknown
- 2020-10-14 ES ES20793780T patent/ES3047908T3/es active Active
- 2020-10-14 EP EP20793780.6A patent/EP4045510B1/en active Active
-
2022
- 2022-03-25 ZA ZA2022/03520A patent/ZA202203520B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022551950A5 (enExample) | ||
| US12479849B2 (en) | EGFR inhibitors for the treatment of cancer | |
| US8957074B2 (en) | Pyrrolopyrimidine compounds as inhibitors of CDK4/6 | |
| US20250122222A1 (en) | Heterocyclic compounds and methods of use | |
| US20250059179A1 (en) | Heterocyclic Compounds and Methods of Use | |
| US20240417412A1 (en) | Heterocyclic compounds and methods of use | |
| US20250163064A1 (en) | Quinazoline compounds and uses thereof as inhibitors of mutant kras proteins | |
| JP2021521165A5 (enExample) | ||
| JP2024517693A5 (enExample) | ||
| US20250289801A1 (en) | Egfr inhibitors | |
| JP2025525356A (ja) | アザキナゾリン汎Ｋｒａｓ阻害剤 | |
| US20240317721A1 (en) | Pyrazolyl derivatives as inhibitors of the kras mutant protein | |
| US20240124474A1 (en) | Her2 mutation inhibitors | |
| JP2018500376A5 (enExample) | ||
| US8288396B2 (en) | Pyrimidopyrimidoindazole derivative | |
| US11236104B2 (en) | Heteroaromatic NMDA receptor modulators and uses thereof | |
| JP2017531672A5 (enExample) | ||
| EP4419525B1 (en) | Heterocyclic compounds for use in the treatment of cancer | |
| US11702414B2 (en) | Thiadiazole IRAK4 inhibitors | |
| US12590099B2 (en) | Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection | |
| JP2018535958A5 (enExample) | ||
| JP2024511841A5 (enExample) | ||
| JP2024539130A (ja) | がんの治療における使用のためのヘテロ環式化合物 | |
| JP2022508523A5 (enExample) | ||
| US12180226B2 (en) | Spirotricycle RIPK1 inhibitors and methods of uses thereof |